Literature DB >> 17351362

Antioxidant activity of carvedilol in cardiovascular disease.

Paresh Dandona1, Husam Ghanim, David P Brooks.   

Abstract

Oxidative and inflammatory stresses are cardinal in the pathogenesis of hypertension and atherosclerosis. Oxidative stress also leads to the induction of inflammation through the activation of proinflammatory transcription factors. Understanding the mechanisms leading to oxidative stress and the means of suppressing it are important in controlling complications related to atherogenesis, since oxidative and inflammatory stress are important in the pathogenesis of atherosclerosis. The failure of chemical antioxidants [which scavenge reactive oxygen species (ROS)], such as vitamins E and C, has led to further exploration of the ROS-suppressive effects of drugs used in the treatment of cardiovascular disease. Carvedilol has been shown to possess both ROS-scavenging and ROS-suppressive effects, and its use is associated with a reduction in oxidative stress. Furthermore, anti-inflammatory effects of carvedilol have now been described. Although further clinical investigations are required, these properties may contribute to the improvement in clinical outcomes observed with carvedilol.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17351362     DOI: 10.1097/HJH.0b013e3280127948

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  38 in total

Review 1.  [Perioperative beta-receptor blockade. For and against].

Authors:  B Preckel; M Poels; F Wappler; W Schlack; W Buhre
Journal:  Anaesthesist       Date:  2010-07       Impact factor: 1.041

Review 2.  Monoamine oxidases (MAO) in the pathogenesis of heart failure and ischemia/reperfusion injury.

Authors:  Nina Kaludercic; Andrea Carpi; Roberta Menabò; Fabio Di Lisa; Nazareno Paolocci
Journal:  Biochim Biophys Acta       Date:  2010-09-24

3.  Short-term use of telmisartan attenuates oxidation and improves Prdx2 expression more than antioxidant β-blockers in the cardiovascular systems of spontaneously hypertensive rats.

Authors:  Sae Mi Yoo; Sung Hyun Choi; Monica Dha Yea Jung; Sung Cil Lim; Sang Hong Baek
Journal:  Hypertens Res       Date:  2014-10-16       Impact factor: 3.872

Review 4.  The β2-adrenergic receptor-ROS signaling axis: An overlooked component of β2AR function?

Authors:  Kalyn M Rambacher; Nader H Moniri
Journal:  Biochem Pharmacol       Date:  2019-11-05       Impact factor: 5.858

5.  Carvedilol as a potential novel agent for the treatment of Alzheimer's disease.

Authors:  Jun Wang; Kenjiro Ono; Dara L Dickstein; Isabel Arrieta-Cruz; Wei Zhao; Xianjuan Qian; Ashley Lamparello; Rakesh Subnani; Mario Ferruzzi; Constantine Pavlides; Lap Ho; Patrick R Hof; David B Teplow; Giulio M Pasinetti
Journal:  Neurobiol Aging       Date:  2010-07-01       Impact factor: 4.673

6.  Acute myocarditis in bodybuilder from coxsackievirus and thyrotoxicosis.

Authors:  Tommy Kwak; Moamen Al Zoubi; Aruni Bhavith; Carlos Rueda Rios; Surender Kumar
Journal:  J Cardiol Cases       Date:  2016-07-20

7.  Resveratrol inhibits foam cell formation via NADPH oxidase 1- mediated reactive oxygen species and monocyte chemotactic protein-1.

Authors:  Dae Weon Park; Kheewoong Baek; Jae Ryong Kim; Jae Jin Lee; Sang Ho Ryu; Byung Rho Chin; Suk Hwan Baek
Journal:  Exp Mol Med       Date:  2009-03-31       Impact factor: 8.718

8.  TJ0711, a novel vasodilatory β-blocker, protects SHR rats against hypertension induced renal injury.

Authors:  Juan Yang; Yong Ning; Jun Qiu; Jin-Seng He; Wei Li; Zu-Fu Ma; Ju-Fang Shao; Yue-Qiang Li; Rui Zeng; Meng Zhang; Jia Cheng; Su-Fang Chen; Gang Xu; Cong-Yi Wang; Ying Yao
Journal:  Am J Transl Res       Date:  2013-04-19       Impact factor: 4.060

Review 9.  Controlled-release carvedilol in the management of systemic hypertension and myocardial dysfunction.

Authors:  William H Frishman; Linda S Henderson; Mary Ann Lukas
Journal:  Vasc Health Risk Manag       Date:  2008

Review 10.  Realities of newer beta-blockers for the management of hypertension.

Authors:  Camila Manrique; Thomas D Giles; Keith C Ferdinand; James R Sowers
Journal:  J Clin Hypertens (Greenwich)       Date:  2009-07       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.